A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)

被引：0
|
作者：
Zhang, L. [1 ]
Fang, W. F. [1 ]
Zhao, S. [1 ]
Yu, Y. [2 ]
Yong, T. X. [3 ]
Dong, X. [4 ]
Zhuang, W. [5 ]
Hu, Y. [6 ]
Luo, F. [7 ]
Wang, Q. [8 ]
Chu, Q. [9 ]
Fu, Z. [10 ]
Yao, Y. [11 ]
Ma, X. [12 ]
Ding, C. [13 ]
Hao, J. [14 ]
Yang, X. [14 ]
Wan, X. [14 ]
Li, M. [14 ]
Yang, Y. [14 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[3] Shandong Canc Hosp & Inst, Dept Resp Med, Jinan, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Oncol, Wuhan, Peoples R China
[5] Fujian Prov Canc Hosp, Dept Resp Med, Fuzhou, Peoples R China
[6] Hubei Canc Hosp, Dept Oncol, Wuhan, Peoples R China
[7] Sichuan Univ, West China Hosp, West China Sch Med, Lung Canc Ctr, Chengdu, Peoples R China
[8] Jiangsu Prov Hosp Tradit Chinese Med TCM, Dept Resp Med, Nanjing, Peoples R China
[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[10] Wuhan Univ, Renmin Hosp, Hubei Gen Hosp, Canc Ctr, Wuhan, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China
[12] Qingdao Univ, Affiliated Qingdao Cent Hosp, Canc Ctr, Qingdao, Peoples R China
[13] Fourth Hosp Hebei Med Univ North Gate, Dept Resp Med, Shijiazhuang, Hebei, Peoples R China
[14] CSPC Pharmaceut Grp Co Ltd, Clin Div, Shijiazhuang, Hebei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614MO
引用
收藏
页码：S1624 / S1625
页数：3
相关论文
共 50 条
  • [21] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [22] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
    Thamlikitkul, Lucksamon
    Manocheewa, Siriphan
    Limjiasahapong, Suphitcha
    Wanichthanarak, Kwanjeera
    Panya, Atikorn
    Poungvarin, Naravat
    Pomyen, Yotsawat
    Khoomrung, Sakda
    CANCER RESEARCH, 2024, 84 (06)
  • [23] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
    Kunimasa, Kei
    Kamada, Risa
    Oka, Toru
    Oboshi, Makiko
    Kimura, Madoka
    Inoue, Takako
    Tamiya, Motohiro
    Nishikawa, Tatsuya
    Yasui, Taku
    Shioyama, Wataru
    Nishino, Kazumi
    Imamura, Fumio
    Kumagai, Toru
    Fujita, Masashi
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 1 - 10
  • [24] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2025,
  • [25] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [26] Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
    Di Marino, Pietro
    Chiapperino, Cosima
    Primavera, Francesca Chiara
    Martino, Maria Teresa
    Brocco, Davide
    Carella, Consiglia
    Grassadonia, Antonino
    Tinari, Nicola
    De Tursi, Michele
    ONCOTARGETS AND THERAPY, 2022, 15 : 407 - 410
  • [27] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
    Mak, D. Y.
    Yan, M.
    Cheung, P.
    Parmar, A.
    Poon, I.
    Ung, Y.
    Tsao, M.
    Warner, A.
    Louie, A. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S497 - S497
  • [28] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [29] Osimertinib in Relapsed EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases: Results from the TREM-Study
    Eide, I. J.
    Helland, A.
    Borrisova, S.
    Ekman, S.
    Cicenas, S.
    Koivunen, J.
    Gronberg, B. H.
    Brustugun, O. T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2139 - S2140
  • [30] Pathological assessment of osimertinib-associated cardiotoxicity in EGFR-mutated non-small cell lung cancer patients
    Oka, T.
    Kamada, R.
    Kunimasa, K.
    Oboshi, M.
    Nishikawa, T.
    Yasui, T.
    Shioyama, W.
    Miyashita, Y.
    Koyama, T.
    Kumagai, T.
    Fujita, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 881 - 881
12345